Zevalin Price Negotiations Will Be Model For Medicare Part B, Scully Says

Idec's experience securing Medicare reimbursement for Zevalin should be considered the model for how coverage decisions will work for new products once Part B payment reforms are implemented in 2005, former CMS Administrator Tom Scully said

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet